Depression
Depression is a chronic mental health condition characterized by a persistent state of low mood, hopelessness, apathy, and fatigue, which lasts for weeks or months and significantly interferes with daily life. Unlike sadness, it is a disorder that requires attention and intervention.
Health Outcomes
- Absence of Biogenic Amines Production
- Absence of Severe Adverse Events
- Activation of G-Protein Coupled Receptors
- Alleviated D-Tryptophan Levels
- Altered Brain Activity to Negative Emotional Stimuli
- Altered Catecholamine Level
- Altered Endocannabinoid System Function Due to Specific Strain
- Altered Monoamine Signaling
- Altered Neurobiological Markers
- Altered Pyridoxine Concentration
- Attenuated Stress-Induced Changes in Gut Microbiota
- Beneficial Clinical Effects
- Changed Leukocyte Telomere Length
- Changes in Health Status from Probiotic Intervention
- Comparable Tolerability
- Elevated Serum Tryptophan Levels
- Enhanced BDNF-TrkB Signaling
- Enhanced Brain-Derived Neurotrophic Factor Levels
- Enhanced Neurogenesis in Adults
- Enhanced Neuropharmacological Function
- Enhanced Orbitofrontal Cortex Activation
- Enhanced Parasympathetic Nervous System Activity
- Enhanced Placebo Response
- Enhanced Serotonin Pathway Function
- Enhanced Stress Resistance
- Formation of Biogenic Amines
- High Treatment Acceptability
- Improved Adherence Ability
- Improved Antidepressant Response
- Improved Antidepressant Support
- Improved Autonomic Balance
- Improved Behavioral Elements
- Improved Behavioral Health
- Improved Brain-Derived Neurotrophic Factor Level
- Improved Clinical Outcomes
- Improved Cognitive Reactivity to Sad Mood
- Improved Cognitive Score
- Improved Consumer Acceptance
- Improved Coping Strategies
- Improved Depression Status
- Improved Depression Symptoms
- Improved Distress of Life Score
- Improved Efficacy Rate
- Improved Emotional Processing
- Improved Emotional State
- Improved Emotional Well-Being Quality of Life
- Improved Emotional Well-being
- Improved Energy Levels
- Improved Enjoyment of Life
- Improved Erectile Function
- Improved Fatigue Index
- Improved Feeling of Well-being
- Improved Folate Levels
- Improved General Activity
- Improved General Behavioral Scores
- Improved General Health
- Improved General Well-Being
- Improved Global Clinical Impression
- Improved Global Quality of Life
- Improved Glucocorticoid Negative Feedback on the HPA Axis
- Improved Gut-Brain Axis Function
- Improved Gut-Brain Axis Homeostasis
- Improved Gut-Brain Axis Related Neurobehavioral Measures
- Improved Gut-Brain Axis-Related Neuropsychiatric Health
- Improved HPA Axis Response
- Improved Health Condition
- Improved Health Outcomes
- Improved Health Perception
- Improved Health Status
- Improved Health Status Score
- Improved Health in Elderly Populations
- Improved Health-related Quality of Life
- Improved Heart Rate Variability
- Improved High-Frequency Power
- Improved Human Health
- Improved Management of Celiac Disease
- Improved Mental Health
- Improved Mental Well-Being
- Improved Mood
- Improved Motivation to Move
- Improved Neuroendocrine Stress Markers
- Improved Neuropsychiatric Outcomes
- Improved Neurotransmitter Metabolism
- Improved Neurotransmitter Profile
- Improved Overall Health
- Improved Overall Symptom Relief
- Improved Overall Symptoms
- Improved Parent/Caregiver Health-Related Quality of Life
- Improved Parental Mood
- Improved Patient Satisfaction
- Improved Pattern Separation
- Improved Perceived Health
- Improved Perceived Mental Well-being
- Improved Perceived Recovery
- Improved Physical Quality of Life
- Improved Physical and Psychological Performance
- Improved Positive Affect
- Improved Presenteeism
- Improved Processing Speed
- Improved Productive Performance
- Improved Proportion of Healthy Days
- Improved Psychological Status
- Improved Psychological Well-being
- Improved Psychological Wellbeing
- Improved Psychosocial Health-Related Quality of Life
- Improved Quality of Life
- Improved Quality of Life for IBS-D Patients
- Improved Quality of Life in Individuals with Crohn's Disease
- Improved Regulation of HPA Axis
- Improved Satisfaction
- Improved Secondary Symptoms
- Improved Self-Rated Vigor
- Improved Self-Sufficiency
- Improved Serotonin Metabolism
- Improved Set Shifting Ability
- Improved Sex Life
- Improved Sleep Maintenance
- Improved Sleep-Related Recovery in Participants with High Chronic Stress
- Improved Social Function
- Improved Social Functioning
- Improved Social Functioning Quality of Life
- Improved Socialization
- Improved Stress Management
- Improved Stress-Related Psychiatric Health
- Improved Subjective Recovery
- Improved Swimming Performance
- Improved Sympathetic Tone
- Improved Symptom Score
- Improved Symptoms
- Improved Therapeutic Consistency
- Improved Therapy Acceptability
- Improved Total DASS-42 Score
- Improved Total SODA Scores
- Improved Treatment Success
- Improved Vagal Reactivation
- Improved Various Elements
- Improved Waking Quality
- Improved Well-Being
- Improved Work Capacity
- Improved Work Performance
- Improved Working Memory
- Increased 5-Hydroxytryptophan Levels
- Increased Acceptability of Use
- Increased Attachment Gain
- Increased BDNF Levels in the Prefrontal Cortex
- Increased Beneficial Gut Bacteria
- Increased Bifidobacteria Levels in Gut Microbiota
- Increased Brain Choline Level
- Increased Brain-Derived Neurotrophic Factor Levels
- Increased Cortisol Levels
- Increased Distractibility
- Increased Energy Levels
- Increased Folate Levels
- Increased General Morbidity
- Increased Heart Rate Variability
- Increased Insomnia
- Increased Irritability
- Increased Myo-Inositol Level
- Increased Negative Transcriptional Regulation
- Increased Neurogenesis
- Increased Oxytocin Synthesis in the Hypothalamus
- Increased Physical Activity
- Increased Plasma Omega-3 Fatty Acids
- Increased Plasma Serotonin Levels
- Increased Plasma Tryptophan Concentration
- Increased Prefrontal Cortex Deoxygenated Hemoglobin Level
- Increased Proportion of Healthy Days
- Increased Salivary Secretory Immunoglobulin A Levels
- Increased Serotonin 2A Receptor Levels
- Increased Serotonin Levels
- Increased Serotonin Production
- Increased Serum Serotonin Levels
- Increased Social Avoidance
- Increased Stress Biomarkers
- Increased Systemic GABA Levels
- Increased Treatment Effectiveness
- Increased Treatment Responders
- Increased Voluntary Physical Activity
- Increased Voluntary Wheel Running
- Increased n-3 Polyunsaturated Fatty Acid Levels
- Induced Circadian Rhythm-Dependent Short-Chain Fatty Acid Production by Gut Microbiota
- Maintained Normal Behavior
- Maintained Physical Activity Level
- Maintained Positive Mood Under Stress
- Maintained Secretory IgA Levels
- Modified Resting-State Brain Connectivity
- Modulated Endocannabinoid System
- Modulated HPA Axis
- Modulated Microbiota-Gut-Brain Axis
- No Adverse Effects on Food Intake
- No Adverse Health Effects
- No Adverse Safety Findings
- No CYP1A2 or CYP3A4 Interaction
- No Change in Anxiety
- No Change in Appetite Parameters
- No Change in Body Composition
- No Change in Circulating Cytokines
- No Change in Complete Symptom Cessation
- No Change in Interleukin-10 Levels
- No Change in Negative Mood States
- No Change in Oxidative Stress Markers
- No Change in Plasma GABA Levels
- No Change in Serum Cytokine Levels
- No Change in Subjective Appetite
- No Clear Clinical Benefit
- No Conclusive Efficacy
- No Improvement in IBS Symptoms
- No Significant Change in Blood Indices
- No Significant Changes in Immune Parameters
- No Significant Difference Compared to Placebo
- No Significant Impact on Immune Response to KLH Immunization
- No Significant Weight Change
- Normalized Cortisol Levels
- Normalized HPA Axis Activity
- Normalized Neurotransmitter Levels
- Notable Overall Improvement
- Preserved Hippocampal Neurogenesis
- Reduced Adherence Attrition
- Reduced Anger
- Reduced Anhedonia
- Reduced Appetite
- Reduced Appetite Changes
- Reduced Appetite Loss Incidence
- Reduced Appetite Sensation Score
- Reduced Brain Inflammation
- Reduced Chemokine C-C Motif Ligand 2 Level
- Reduced Chocolate Pleasantness Rating
- Reduced Composite Score
- Reduced Concomitant Medication Usage
- Reduced Corticosterone Levels
- Reduced Cortisol Levels
- Reduced Cost-Effectiveness in Reducing AAD
- Reduced D-Tryptophan Levels
- Reduced DASS-21 Score
- Reduced DOPAC Levels in Amygdaloid Cortex
- Reduced Daily Life Disturbance
- Reduced Day School Absenteeism
- Reduced Depressed Mood
- Reduced Depression
- Reduced Depression Score
- Reduced Depression Severity
- Reduced Depressive Affect
- Reduced Depressive Symptom
- Reduced Depressive Symptoms
- Reduced Depressive Symptoms Post-Myocardial Infarction
- Reduced Depressive Symptoms Postpartum
- Reduced Depressive Thoughts
- Reduced Discontinuation Rates
- Reduced Disturbed Sleep Night
- Reduced Doctor Visits
- Reduced Dopamine Levels
- Reduced Energy Intake
- Reduced Fecal Cortisol Levels
- Reduced Folic Acid Level
- Reduced Food Intake
- Reduced Frequency of Disturbed Sleep
- Reduced Glutamate Level
- Reduced Gut Bacteria Associated with Mental Illness
- Reduced HADS Global Score
- Reduced HPA Axis Hyperactivity
- Reduced Hamilton Depression Rating Scale Score
- Reduced Health Distress
- Reduced Heart Rate Variability
- Reduced Homocysteine Level
- Reduced Incidence of Crying
- Reduced Indoleamine 2,3-Dioxygenase Activity
- Reduced Insomnia
- Reduced Kynurenine-Tryptophan Ratio
- Reduced Mean Total Severity per Day in Reported Episodes
- Reduced NREM Sleep Quality
- Reduced Negative Mood States
- Reduced Non-Pain Symptoms
- Reduced Overall Symptom Score
- Reduced Overall Symptoms
- Reduced Perceived Stress
- Reduced Physical Activity
- Reduced Physical Symptoms of Stress
- Reduced Plasma LPS Levels
- Reduced Polyamine Levels
- Reduced Post-Exercise Cortisol Response
- Reduced Prefrontal Cortex Oxygenated Hemoglobin
- Reduced Prefrontal Cortex Total Hemoglobin Level
- Reduced Prospective Consumption
- Reduced Psychological Distress
- Reduced Psychopathology Symptoms
- Reduced Reaction Time
- Reduced Rearing Behavior
- Reduced Recurrence Risk
- Reduced Relative Abundance of Coprococcus Genus
- Reduced Risk of Crying
- Reduced Salivary Alpha-Amylase Level
- Reduced Salivary IgA Levels
- Reduced Salivary Serotonin Levels in Response to Stress
- Reduced Serum BDNF Levels
- Reduced Serum Cortisol Levels
- Reduced Serum Glutamate Levels
- Reduced Serum IL-6 Levels
- Reduced Serum Kynurenine Levels
- Reduced Serum Serotonin Levels
- Reduced Simple Reaction Time
- Reduced Sleep Duration
- Reduced Standard Care Medication Need
- Reduced Stress Biomarkers
- Reduced Stress Hormone Levels
- Reduced Stress Indicators
- Reduced Stress Levels
- Reduced Stress-Induced Reduction in Diurnal Temperature Amplitude
- Reduced Stress-Related Discomfort
- Reduced Subjective Symptoms
- Reduced Sympathetic Nerve Activity
- Reduced Symptom Severity
- Reduced Symptom Severity Scale Score
- Reduced Symptoms
- Reduced Total Mood Disturbance
- Reduced Total Side Effects Incidence
- Reduced Total Symptom Score
- Reduced Treatment Costs
- Reduced Urinary Free Cortisol Levels
- Reduced VIA Positivity
- Reduced cFos Expression in Brain Areas
- Regulated Tryptophan Metabolism
- Regulation of Neuroactive Ligand Receptor Interaction Pathway
- Similar Frequency of Adverse Events
- Stabilized Dopamine Pathway Function
- Stabilized Physiological Stress Markers
- Supportive Effect in Breast Cancer Management
- Symptom Alleviation
- Unchanged Body Weight
- Unchanged Food Intake
- Unchanged Immune Function
- Unchanged Risk of Sepsis
- Unchanged Salivary IgA Levels
- Unchanged Symptom Severity
- Worsened Depression Score
- Worsened IBS Symptoms